Biomarin Pharmaceutical Inc’s recently made public that its GVP, Chief Accounting Officer Burkhart Erin unloaded Company’s shares for reported $92618.0 on Mar 19 ’25. In the deal valued at $71.52 per share,1,295 shares were sold. As a result of this transaction, Burkhart Erin now holds 16,955 shares worth roughly $1.02 million.
Then, Burkhart Erin bought 1,295 shares, generating $92,618 in total proceeds.
Before that, Guyer Charles Greg sold 7,034 shares. Biomarin Pharmaceutical Inc shares valued at $501,355 were divested by the EVP, Chief Technical Officer at a price of $71.28 per share. As a result of the transaction, Guyer Charles Greg now holds 87,655 shares, worth roughly $5.26 million.
Oppenheimer upgraded its Biomarin Pharmaceutical Inc [BMRN] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. William Blair also remained covering BMRN and has decreased its forecast on October 30, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating.
Price Performance Review of BMRN
On Tuesday, Biomarin Pharmaceutical Inc [NASDAQ:BMRN] saw its stock jump 0.59% to $60.02. Over the last five days, the stock has gained 7.39%. Biomarin Pharmaceutical Inc shares have fallen nearly -8.69% since the year began. Nevertheless, the stocks have fallen -34.92% over the past one year. While a 52-week high of $94.85 was reached on 03/07/25, a 52-week low of $52.93 was recorded on 04/09/25. SMA at 50 days reached $67.24, while 200 days put it at $72.13.
Levels Of Support And Resistance For BMRN Stock
The 24-hour chart illustrates a support level at 59.45, which if violated will result in even more drops to 58.88. On the upside, there is a resistance level at 60.76. A further resistance level may holdings at 61.50. The Relative Strength Index (RSI) on the 14-day chart is 38.68, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.47, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.99%. Stochastics %K at 29.17% indicates the stock is a holding.
How much short interest is there in Biomarin Pharmaceutical Inc?
A steep rise in short interest was recorded in Biomarin Pharmaceutical Inc stocks on 2025-03-31, growing by 0.45 million shares to a total of 4.69 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 4.24 million shares. There was a rise of 9.54%, which implies that there is a positive sentiment for the stock.
